Editorial
doi: 10.3109/07357900009032820.
Renal cancer immunotherapy: a ray of hope or regression to the mean?
- PMID: 10834033
- DOI: 10.3109/07357900009032820
Item in Clipboard
Editorial
Renal cancer immunotherapy: a ray of hope or regression to the mean?
Cancer Invest.
2000.
No abstract available
Comment on
-
Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer.Cancer Invest. 2000;18(5):417-21. doi: 10.3109/07357900009032812. Cancer Invest. 2000. PMID: 10834025 Clinical Trial.
Similar articles
-
Immunotherapy for renal carcinoma: theoretical basis and current standard of care.Br J Clin Pharmacol. 2000 Dec;50(6):521-9. doi: 10.1046/j.1365-2125.2000.00300.x. Br J Clin Pharmacol. 2000. PMID: 11136291 Free PMC article. Review. No abstract available.
-
Immunotherapy for renal cell carcinoma.Hematol Oncol Clin North Am. 2011 Aug;25(4):793-812. doi: 10.1016/j.hoc.2011.04.010. Hematol Oncol Clin North Am. 2011. PMID: 21763968 Review.
-
[Immunotherapy for advanced renal cell cancer].Urologe A. 2015 May;54(5):716-20. doi: 10.1007/s00120-015-3825-0. Urologe A. 2015. PMID: 25987336 German. No abstract available.
-
Immunotherapy for metastatic renal cell carcinoma.BJU Int. 2007 May;99(5 Pt B):1282-8. doi: 10.1111/j.1464-410X.2007.06818.x. BJU Int. 2007. PMID: 17441925 Review. No abstract available.
-
Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.J Clin Oncol. 2006 Dec 10;24(35):5584-92. doi: 10.1200/JCO.2006.08.1638. J Clin Oncol. 2006. PMID: 17158544 Review.
Cited by
-
Specific immunotherapy in renal cancer: a systematic review.Ther Adv Urol. 2017 Feb;9(2):45-58. doi: 10.1177/1756287216681246. Epub 2016 Dec 19. Ther Adv Urol. 2017. PMID: 28203287 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
